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subsets following stimulation with 
ligands for intracellular Toll-like 
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The opioid antagonist naltrexone hydrochloride has been suggested to be a potential 
therapy at low dosage for multiple inflammatory conditions and cancers. Little is known 
about the immune-modulating effects of naltrexone, but an effect on the activity of toll-like 
receptor 4 (TLR4) has been reported. We analyzed the effects of naltrexone hydrochloride 
on IL-6 secretion by peripheral blood mononuclear cells (PBMC) in vitro following stim-
ulation with ligands for TLR4 and for the intracellular receptors TLR7, TLR8, and TLR9. 
Naltrexone did not affect cell viability or induce apoptosis of PBMC. Intracellular staining 
demonstrated that naltrexone inhibited production of IL-6 and TNFα by monocyte and 
plasmacytoid dendritic cell subsets within the PBMC population following treatment 
with ligands for TLR7/8 and TLR9, respectively. No effect of cytokine production by 
PBMC following stimulation of TLR4 was observed. Additionally, naltrexone inhibited 
IL-6 production in isolated monocytes and B cells after TLR7/8 and TLR9 stimulation, 
respectively, but no effect on IL-6 production in isolated monocytes after TLR4 stimulation 
was observed. These findings indicate that naltrexone has the potential to modulate the 
secretion of inflammatory cytokines in response to intracellular TLR activity, supporting 
the hypothesis that it may have potential for use as an immunomodulator.
Keywords: toll-like receptor, naltrexone, interleukin-6, tumor necrosis factor alpha, plasmacytoid dendritic cells, 
B cells, monocytes
inTrODUcTiOn
Naltrexone hydrochloride is an opioid antagonist used commonly in the treatment of opioid and 
alcohol dependence (1, 2). Naltrexone specifically inhibits the mu and, to a lesser extent, the delta 
opioid receptors (3), thus preventing the euphoric effects of alcohol or opioid. It has been suggested 
that treatment with low-dose naltrexone (LDN) may be beneficial for a range of inflammatory 
conditions, including Crohn’s disease (4), multiple sclerosis (5), and fibromyalgia (6–8). Reports 
also describe therapeutic effects of LDN in treatment for cancers including B cell lymphoma (9) and 
pancreatic cancer (10, 11). The molecular targets and potential immunomodulatory mechanism(s) 
of action for naltrexone in inflammatory conditions, however, require further investigation. Studies 
by Zagon et al. indicate that naltrexone can inhibit the non-canonical opioid growth factor receptor, 
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resulting in a decrease in cell proliferation (12–14). Naltrexone 
and the related opioid antagonist naloxone have also been shown 
to inhibit the activity of a member of the toll-like receptor (TLR) 
family, TLR4, in an in vitro signaling assay and to reverse neuro-
pathic pain in an animal model (15, 16).
Toll-like receptors recognize conserved molecular patterns 
and nucleic acids as part of the innate immune response (17). Ten 
members of the TLR family have been described in humans and 
these vary in their cellular location; TLR1, TLR2, TLR4, TLR5, 
TLR6 and TLR10 are expressed on the cell surface, where they 
can detect components of extracellular pathogens and some self-
ligands, while TLR3, TLR7, TLR8, and TLR9 are located within 
endosomes where they respond to the presence of viral, bacterial, 
and self-nucleic acids (18). TLRs also vary in their expression 
profile between immune cell subsets. For example, B cells express 
TLR1, TLR6, TLR7, and TLR9 (19), while monocytes express 
TLR1, TLR2, TLR4, TLR7, and TLR8 (19, 20) and plasmacytoid 
dendritic cells express TLR7 and TLR9 (19, 21).
Although TLRs play a key role in the initiation of immune 
responses to infection, inappropriate TLR activity and/or recog-
nition of self-ligands are associated with inflammatory conditions 
and autoimmunity (22). For example, increased expression of 
TLRs has been observed in peripheral B cells from patients with 
inflammatory bowel disease (23), while recognition of self-DNA 
complexes by TLR9 mediates pDC activation in psoriasis (24). 
TLRs have also been implicated in the tumor microenvironment, 
with TLR activation linked to angiogenesis, tumor proliferation, 
and immune evasion (25). Furthermore, some TLR polymor-
phisms may be associated with development of inflammatory 
conditions such as Crohn’s disease (26, 27). TLRs have, therefore, 
been investigated as potential therapeutic targets in patients with 
these diseases (28, 29).
In this study, we sought to investigate the ability of naltrexone 
hydrochloride to inhibit the effects of TLR4 signaling in an 
immune context and to determine whether its inhibitory effects 
extend to other members of the TLR family. Our results indicate 
that naltrexone can inhibit production of the inflammatory 
cytokines IL-6 and TNFα by peripheral blood mononuclear cells 
(PBMC) following stimulation with known ligands for TLR7, 
TLR8, and TLR9 but not following stimulation with a TLR4 
ligand. Although the interleukin 1 receptor (IL-1R) shares the 
MyD88 signaling pathway with members of the TLR family, IL-6 
secretion following IL-1R stimulation was not affected by naltrex-
one. Our findings also indicate that naltrexone does not affect cell 
viability or induce apoptosis within the PBMC population.
MaTerials anD MeThODs
ethics statement
This study was carried out in accordance with the recommen-
dations of St George’s, University of London Research Ethics 
Committee (Protocol Approval SGREC15.0006). All subjects 
gave written informed consent.
cell culture
Peripheral blood mononuclear cells were isolated from leukocyte 
cones (NHS Blood Donor Service) by density centrifugation over 
Histopaque (Sigma-Aldrich) according to the manufacturer’s 
instructions. PBMC were resuspended at a concentration of 106 
PBMC/ml in RPMI-1640 (Sigma-Aldrich) supplemented with 
10% fetal bovine serum (Sigma-Aldrich), penicillin, and strep-
tomycin (Sigma-Aldrich). PBMC viability was assessed using 
trypan blue dye exclusion using the BioRad TC20 Automated Cell 
Counter (BioRad). PMBC with a viability of above 90% were used 
in assays. PBMC were plated onto 24 well plates and cultured at 
standard cell culture conditions at 37°C, 5% CO2.
cell stimulation
The following ligands were used to stimulate cells: 1  ng/ml 
LPS-EB Ultrapure, 1µM CPG-ODN 2395, 1µM R848, and 
100 ng/ml IL-1 (all Invivogen). For isolated B cell experiments, 
CD40R was cross-linked using 3 µg/ml CD40-L (R&D Biosource) 
with anti-HA monoclonal antibody (Sigma-Aldrich) and 20 ng/
ml IL-4 (R&D Biosource). Lyophilized ligands were resuspended 
in endotoxin-free water as detailed in the manufacturer’s instruc-
tions. Ligands were further diluted in RPMI before being added 
to PBMC at the concentrations stated. Naltrexone hydrochloride 
(Sigma-Aldrich) was resuspended in endotoxin-free water and 
diluted in RPMI before being added to PBMC at the working 
concentrations specified.
isolation of cD14+ and cD19+ cells
Positive selection of CD14+ and CD19+ was performed by 
incubating PBMC with MACS CD14+ and CD19+ microbeads 
in MACS buffer, according to the manufacturer’s instructions 
(Miltenyi Biotec). After incubation of cells and microbeads, cells 
were washed with MACS buffer, resuspended in MACS buffer, 
and loaded onto a MACS column attached to a magnetic field 
of a MACS separator. After being washed with MACS buffer 
three times, the column was removed from the magnetic field 
and the CD14+ and CD19+ cells were eluted using MACS buffer 
(Miltenyi Biotec). Purity of above 90% was confirmed by flow 
cytometry using CD14-VioBlue mIgG1 antibody and CD20 
FITC mIgG1 antibody (Miltenyi Biotec).
il-6 elisa
106 PBMC were stimulated with ligands and naltrexone as stated 
above for 24  h before cell-free supernatants were collected 
and IL-6 ELISA was performed using an IL-6 ELISA kit (BD 
Bioscience) as per manufacturer’s instructions. Optical densities 
were measured using GloMax-Multi+ Microplate with Instinct 
microplate reader (Promega). Data were then analyzed using a 
5-parameter sigmoidal curve on Graph Pad Prism Version 7.
intracellular cytokine staining
106 PBMC were stimulated with TLR ligand (TLR-L) and nal-
trexone for 6 h in the presence of brefeldin A (eBioscience) for 
4 of those hours. After 6 h, PBMC were washed with PBS and 
cell surface markers were stained using fluorochrome-conjugated 
monoclonal antibodies. Antibodies used were CD14-VioBlue, 
mIgG1, clone TUK4, CD1c-VioBright FITC, mIgG2a clone 
AD5-8E7, CD303 PE-Vio770, mIgG1, clone AC144 (all Milenyi 
Biotec) and CD19-PE, mIgG1, clone HIB19 (eBioscience), or 
appropriate isotype. After washing in PBS, PBMC were fixed and 
FigUre 1 | Naltrexone inhibits IL-6 production after toll-like receptor (TLR)7/8 and TLR9 stimulation but not after TLR4 or IL-1 stimulation. 1 × 106 peripheral blood 
mononuclear cells were incubated with (a) 1 ng/ml LPS (TLR4-L), (B) 1µM R848 (TLR7/8-L), (c) 1µM CpG (TLR9-L), (D) 100 ng/ml IL-1 (IL-1R) in the presence or 
absence of 1–200µM naltrexone for 24 h. Cell-free supernatants were collected and analyzed for IL-6 by ELISA. Data show the mean; SD values are shown and 
were analyzed using an one-way ANOVA and Tukey’s multiple comparison test (n = 5 TLR ligand experiments and n = 3 IL-1). *p < 0.05.
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permeabilized using BD cell fixation/permeabilization kit. PBMC 
were then washed in BD perm/wash buffer and stained for IL-6 
and TNF-α using TNFα, hIgG1, clone cA2 (Milentyi Biotec) or 
IL-6 APC, rIgG1, clone MQ2-13A5 (eBioscience), or appropri-
ate isotype. After washing with BD perm/wash buffer, PBMC 
were ran on the BD Canto running BD FACSDiva software and 
analyzed using FlowJo software.
Flow cytometry analysis
Unstained PBMC and fluorescence minus one (FMO) controls, 
in combination with appropriate isotype controls, were used to 
determine gating. Figure S4 in Supplementary Material shows 
the gating strategy, and all flow cytometry data were analyzed 
using FlowJo software. PBMC population was gated based on 
the size (FSC) and granularity (SSC) of the cells. CD14+ and 
CD19+ were used to identify monocytes and B cells, respectively. 
Within the CD14− CD19− population, myeloid dendritic cells 
and plasmacytoid dendritic cells were identified by CD1c and 
CD303 positivity, respectively. To determine the expression of 
the intracellular cytokines, histograms were generated to deter-
mine the percentage of subsets that is positive for the marker 
or cytokine of interest. IL-6 and TNFα positive and negative 
populations were gated based on FMO in combination with 
isotype control. Mean fluorescence intensity of TNFα and IL-6 
was also determined.
cell Viability
One million PBMC were stimulated with TLR-L and naltrexone 
for 24 h before being resuspended in 1× annexin V binding buffer 
(eBioscience) and incubated with 5 µl annexin V APC (eBiosci-
ence) for 20 min. Cells were then washed in 1 ml 1× annexin V 
binding buffer and resuspended in 200 µl 1× annexin V binding 
buffer. 5 µl 7AAD was then added, and data were collected using 
the BD Canto. Data were analyzed using FlowJo software.
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statistics
Data are presented as mean with the SEM, and statistical analysis 
was performed using GraphPad Prism version 6.07 for Windows. 
Data were analyzed using an one-way ANOVA and Tukey’s mul-
tiple comparison test. A p value of below 0.05 was deemed to be 
significant.
resUlTs
naltrexone inhibits il-6 Production 
induced after Tlr7/8 and Tlr9 but not 
Tlr4 or il-1r stimulation
It has previously been shown that naltrexone inhibits TLR4 activ-
ity both in an in vitro assay system and in microglial cells (15, 
16). We therefore sought to determine the effect of naltrexone 
on this and other members of the TLR family in an immune 
context, focusing on production of IL-6, a key cytokine produced 
following TLR stimulation. Titrations were performed in order 
to determine the optimum concentration of TLR-Ls that induce 
statistically significant IL-6 production in PBMC (Figure S1 in 
Supplementary Material). PBMC were stimulated with TLR-Ls 
for TLR4 (LPS 1 ng/ml), TLR7/8 (R848 1µM), and TLR9 (CpG 
1µM) in the presence or absence of naltrexone (1–200µM), 
and IL-6 production was determined by ELISA. Naltrexone 
had no effect on IL-6 production following TLR4 stimulation 
(Figure 1A); however, 200µM naltrexone inhibited IL-6 produc-
tion following stimulation with ligands for TLR7/8 (Figure 1B, 
p < 0.05) and TLR9 (Figure 1C, p < 0.05) (these data are also 
presented as dose response curves in Figure S2 in Supplementary 
Material). As R848 is a ligand for both TLR7 and TLR8, we 
sought to determine if naltrexone inhibits IL-6 production after 
TLR7 (R837 3 µg/ml) or TLR8 (ssRNA 0.5 µg/ml) stimulation. 
Naltrexone inhibited IL-6 production after both TLR7 and TLR8 
stimulation in a dose-dependent manner, although this did not 
reach significance (Figure S3 in Supplementary Material). As 
TLR7, TLR8, and TLR9 signal via the MyD88 pathway, whereas 
TLR4 can signal via both MyD88-dependent and -independent 
pathways (28, 30), we hypothesized that naltrexone may affect 
the MyD88-dependent signaling pathway and that any effects of 
naltrexone on IL-6 secretion via TLR4 were compensated for by 
signaling through the MyD88-independent pathway. Stimulation 
of the IL-1R also results in induction of the MyD88-dependent 
pathway and the secretion of IL-6. However, when PBMC were 
stimulated with IL-1 (100 ng/ml) in the presence of naltrexone 
(1–200µM), no effect on IL-6 production observed (Figure 1D).
naltrexone inhibits intracellular cytokine 
Production after Tlr7/8 and Tlr9 
stimulation but not Tlr4 stimulation
In order to determine which subset(s) of cells within the PBMC 
population were effected by naltrexone, intracellular cytokine 
staining was performed. In addition to IL-6 production we 
also examined the effect naltrexone has on another signature 
cytokine produced after TLR stimulation, TNF-α. PBMC were 
stimulated with TLR-L (LPS 1 ng/ml, R848 1µM, and CpG 1µM) 
and 200µM naltrexone for 6  h, with the addition of brefeldin 
A after 2  h. PBMC were then stained for cell surface markers, 
as shown in Figure S4 in Supplementary Material, to identify 
monocytes (CD14+), B  cells (CD19+), myeloid dendritic cells 
(CD14− CD19− CD1c+, mDCs), and plasmacytoid dendritic 
cells (CD14− CD19− CD1c− CD303+, pDCs) and for intra-
cellular IL-6 or TNFα (Figure  2). Monocytes were identified 
as a major source of IL-6 following LPS and R848 stimulation 
(Figures 2A,B). In line with our observations from ELISA data 
described above, naltrexone did not appear to affect IL-6 pro-
duction by CD14+ cells following LPS stimulation (Figure 2B). 
A decrease in IL-6 production in monocytes after R848 and 
naltrexone incubation was observed, although this did not reach 
statistical significance (Figure  2B). Incubation with the TLR9 
ligand CpG induced IL-6 production in B cells however, this 
was not altered by the addition of 200μM naltrexone to cultures 
(data not shown). Furthermore, at the time point examined, no 
cytokine production was observed in mDC following incubation 
with LPS, R848, or CpG (data not shown). TNFα was induced 
following LPS and CpG stimulation in monocytes and pDCs, 
respectively (Figures 2C,D). Similar to the results observed for 
IL-6, naltrexone did not affect TNF-α production following LPS 
stimulation in monocytes (Figure 2C), whereas naltrexone did 
inhibit TNF-α production in plasmacytoid dendritic cells follow-
ing TLR9 stimulation (Figure 2D, p < 0.05).
naltrexone inhibits il-6 Production in 
isolated Monocytes and B cells after 
Tlr7/8 and Tlr9 stimulation, 
respectively, but has no effect on il-6 
Production in isolated Monocytes after 
Tlr4 stimulation
To further confirm that naltrexone does not inhibit cytokine 
production after TLR4 stimulation, we isolated CD14+ mono-
cytes from PBMC using magnetic bead isolation. Isolated CD14 
cells were then stimulated with LPS 1 ng/ml and R848 1µM in 
the presence or absence of naltrexone 200µM for 24 h. Cell-free 
supernatants were analyzed for the presence of IL-6 by ELISA. 
Similar to the data obtained from intracellular cytokine analysis 
described above, naltrexone inhibited IL-6 production in mono-
cytes following R848 stimulation, but no effect on LPS-induced 
IL-6 production was observed (Figure 3A). Additionally, within 
the PBMC population, TLR9 is predominately expressed on 
B cells. Therefore, to determine if naltrexone effects IL-6 pro-
duction in isolated B cells after TLR9 stimulation, B cells were 
stimulated with CpG 1µM in the presence of 200µM naltrexone 
for 24  h. Naltrexone inhibited IL-6 production after TLR9 
stimulation but not after cross-linking of CD40R and stimula-
tion with IL-4 (Figure 3B).
naltrexone Does not affect PBMc 
Viability
To ensure that the decreases in IL-6 production we observed in 
the presence of naltrexone were not due to a loss of cell num-
bers, viability was assessed by trypan blue staining following 
FigUre 3 | Naltrexone inhibits IL-6 production in isolated monocytes and B cells after toll-like receptor (TLR)7/8 and TLR9 stimulation, respectively, but has no 
effect on IL-6 production in isolated monocytes after TLR4 stimulation. (a) CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) using 
magnetic bead isolation. 1 × 105 CD14+ cells were incubated with 1 ng/ml LPS (TLR4-L) or 1µM R848 (TLR7/8-L), in the presence or absence of 200µM naltrexone 
for 24 h. Cell-free supernatants were collected and analyzed for IL-6 by ELISA. (B) CD19+ B cells were isolated from PBMC using magnetic bead isolation. 105 
B cells were incubated with 1µM CpG or 3 µg/ml CD40-L and 20 ng/ml IL-4, with or without 200µM naltrexone for 24 h. IL-6 production was measured in cell-free 
supernatants by ELISA. Data show the mean and SD values (n = 4).
FigUre 2 | Intracellular cytokine staining for TNFα and IL-6 in monocytes and plasmacytoid dendritic cells. 1 × 106 peripheral blood mononuclear cells (PBMC) 
were incubated with either LPS 1 ng/ml (a,c), R848 1µM (B), or CpG 1µM (D) and 200 µM naltrexone for 6 h in the presence of brefeldin A for 4 of those hours. 
After 6 h, PBMC were stained using antibody panel shown in Figure S4 in Supplementary Material and stained for either intracellular IL-6 or TNF-α. Results show the 
mean fluorescence intensity (MFI) of IL-6 or TNF-α within that subset from 5 donors. Histograms are representative of 5 independent experiments.
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PBMC incubation with naltrexone (1–200µM) for 24  h. No 
change in cell viability was observed (Figure 4A). Additionally, 
to determine if naltrexone induces apoptosis, annexin V and 
7AAD staining was performed on PBMC following 24 h incu-
bation with naltrexone and TLR-Ls (Figure 4B). As shown in 
Figure  4C, there was no evidence to suggest that TLR-Ls or 
naltrexone incubation induce apoptosis in PBMC at the con-
centrations tested in this study.
DiscUssiOn
Through their roles as mediators of both innate and adaptive 
immune functions, TLRs are powerful agents within the immune 
system. Intracellular TLRs have been investigated as potential 
therapeutic targets for the treatment of inflammatory diseases and 
cancer (29, 31–33). Inhibition of TLR-mediated functions by nal-
trexone could, therefore, indicate a potential immunomodulatory 
FigUre 4 | Toll-like receptor ligand (TLR-L) and naltrexone does not affect the viability of peripheral blood mononuclear cells (PBMC). (a) 1 × 106 PBMC were 
incubated with 1–200µM naltrexone for 24 h before percentage viability was assessed using trypan blue exclusion. (B,c) 1 × 106 PBMC were incubated with 1 ng/
ml LPS (TLR4-L), 1µM R848 (TLR7/8-L), 1µM CpG (TLR9-L), and 200µM naltrexone for 24 h. PBMC were incubated with annexin V and 7AAD before being 
analyzed by flow cytometry. Figure 4B shows the gating strategy, and Figure 4c shows results from 4 donors. AV−7AAD− are viable cells, AV+7AAD− are in early 
apoptosis, and AV+7AAD+ are in late apoptosis.
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relevance for this drug in the treatment of inflammatory disease. 
In this study, we show that naltrexone can inhibit the production 
of cytokines by PBMC following treatment with ligands for the 
intracellular receptors TLR7, TLR8, and TLR9. Flow cytometric 
analysis of individual cell subsets indicated that naltrexone inhib-
ited IL-6 production by monocytes in response to TLR7/8 ligands 
and TNFα production by pDCs in response to TLR9 ligand. These 
reductions in cytokine secretion did not appear to result from a 
loss of cell viability, as no significant effects on cell numbers or 
expression of apoptotic markers was observed.
One unexpected finding of this study was that naltrexone 
did not inhibit cytokine secretion by immune cells following 
stimulation with LPS, a ligand for TLR4. Previously published 
work had shown that naltrexone and naloxone can inhibit 
TLR4-dependent microglial activation, neurodegeneration, and 
nitric oxide production (16, 34) and have identified the LPS 
binding site of the TLR4 co-receptor MD2 as a binding site for 
the drug (35, 36). Previous studies documented the effect of the 
purified isomers of naltrexone on TLR4, whereas our study used 
naltrexone-HCl, a hydrochloride salt commonly prescribed in 
tablet form to patients. Both isomers have shown to bind MD2 
and inhibit TLR4 activity (34, 35) in a HEK-293 reporter cell line 
and rat microglial cells. The (+)-isomer of naltrexone does not act 
on opioid receptors, which may be beneficial for use in therapies 
directed at alternative receptors. Further investigations will be 
necessary to determine the effects of different naltrexone isomers 
on TLR7, TLR8, and TLR9, which are intracellular and do not 
associate with MD2.
Our experiments have shown that naltrexone can inhibit 
cytokine secretion in response to TLR ligands, although further 
work will be required to determine the mechanism(s) of action 
involved. Each of the TLR investigated in the current study 
(TLR4, TLR7, TLR8, and TLR9) signal through the MyD88-
dependent pathway, although TLR4 can also signal via the 
MyD88-independent TRIF pathway. It could be hypothesized 
that inhibition of cytokine production following TLR7, TLR8, 
or TLR9 stimulation results from inhibition of the MyD88 
pathway, and that the observed lack of TLR4 antagonism in our 
experiments results from signaling via TRIF pathway, which can 
induce delayed NFκB activation and resultant IL-6 and TNFα 
production. However, previously published work has suggested 
that naltrexone inhibits phosphorylation of IRF3, a transcrip-
tion factor that downstream of TRIF activation (34). Also, our 
observation that naltrexone did not inhibit cytokine secretion in 
response to stimulation of the IL-1 receptor, which also signals by 
the MyD88 pathway, would support an interaction upstream of 
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this adaptor protein. Further investigations are required to deter-
mine the signaling pathways regulated by naltrexone and how 
this can account for TLRs effected. Furthermore, intracellular 
cytokine assays in this study examined the effect of naltrexone 
on the production of IL-6 and TNFα after 6-h incubation. This 
approach does not provide information of the potential effect 
of naltrexone on cytokine kinetics. More detailed analyses 
determining the effect of naltrexone on cytokine production at 
different time points would be required in order to investigate 
whether naltrexone may delay cytokine production.
The reduction of cytokine secretion observed in the presence 
of naltrexone in our studies did not result from a reduction in 
cell numbers or a decrease in cell viability, as evidenced by dye 
exclusion and flow cytometric analysis for markers of apoptosis. 
This provides further support for our theory that naltrexone can 
modulate immune cell functions through influencing TLR activ-
ity, thus extending the known immune effects of the drug beyond 
the previously documented inhibition of lymphocyte prolifera-
tion in vitro and in vivo (37, 38). However, this study was only 
performed within the whole PBMC population, and therefore it 
is possible that subtle changes in individual immune cell subsets 
within the PBMC population would not be detected. Future stud-
ies would consider the viability of the individual immune subsets 
after incubation with naltrexone.
An ability to modulate TLR activity would provide justifica-
tion to support the use of naltrexone for the treatment of inflam-
matory conditions in which these receptors play a pathogenic 
role. For example, recognition of self-DNA/protein complexes 
by TLR9 mediates pDC activation in psoriasis, breaking self-
immune tolerance (24). Members of the TLR family, including 
TLR9, are often ectopically expressed in tumors (39, 40), can 
induce tumor invasion in vitro (41), and may be an indicator of 
poor prognosis in vivo. Similarly, expression of TLR9 has been 
found to correlate with the invasive and metastatic potential of 
pancreatic carcinoma (42).
Future studies will be required to investigate whether and 
how naltrexone inhibits TLR-mediated inflammatory effects 
in other cell types such as mucosal epithelial cells (43), and 
whether exposure to naltrexone results in upregulation of TLR 
in a similar manner to that seen for its opioid receptor targets 
(44, 45). Additionally, while this study investigated the effect 
of naltrexone on IL-6 and TNFα production, further work 
examining other cytokines, such as IL-12p70, which might be 
induced after multiple TLR stimulation, would provide further 
insights into the ability of naltrexone to modulate immune 
subset activity. It will also be important to consider how the 
potential pleiotropic effects of naltrexone, including inhibition 
of TLR-mediated functions, inhibition of cellular proliferation, 
and other opioid receptor-mediated activity, might contribute to 
its use in the treatment of inflammatory conditions. In this con-
text, it is important to note that previous studies in inflammatory 
diseases and cancer have adopted an LDN regime as opposed to 
the dosages used in the treatment of opioid and alcohol depend-
ency. Nanomolar, but not micromolar, doses of naltrexone were 
previously seen in studies by Liu et al. to result in upregulation 
of pro-apoptotic genes, rendering tumor cells more susceptible 
to chemotherapy (46). It may, therefore, be necessary to identify 
suitable dosage regimes to obtain optimal therapeutic effects on 
individual target pathways in different diseases.
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